Global Bendamustine Market Growth 2025-2031

Publication ID:

LPI01251161

Publication Date:

January 9, 2025

Pages:

103

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Bendamustine market size is predicted to grow from US$ 761 million in 2025 to US$ 720 million in 2031; it is expected to grow at a CAGR of -0.9% from 2025 to 2031.
Bendamustine is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin"s lymphoma. It is given by injection into a vein.
Market competition is intense. Teva, Eisai, Eagle Pharmaceuticals, MundiPharma, Mylan, Natco Pharma, Emcure, etc. are the leaders of the industry, with Teva occupies the major markets share of over 83% in 2018.
The 鈥淏endamustine Industry Forecast鈥� looks at past sales and reviews total world Bendamustine sales in 2024, providing a comprehensive analysis by region and market sector of projected Bendamustine sales for 2025 through 2031. With Bendamustine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bendamustine industry.
This Insight Report provides a comprehensive analysis of the global Bendamustine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bendamustine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Bendamustine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bendamustine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bendamustine.
This report presents a comprehensive overview, market shares, and growth opportunities of Bendamustine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
25mg Injection
100mg Injection
Others
Segmentation by Application:
Chronic Lymphocytic Leukemia
Multiple Myeloma
Non-Hodgkin's Lymphoma
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Teva
Eisai
Eagle Pharmaceuticals
MundiPharma
Mylan
Natco Pharma
Emcure
Miracalus Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Bendamustine market?
What factors are driving Bendamustine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Bendamustine market opportunities vary by end market size?
How does Bendamustine break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Bendamustine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Bendamustine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Bendamustine by Country/Region, 2020, 2024 & 2031
2.2 Bendamustine Segment by Type
2.2.1 25mg Injection
2.2.2 100mg Injection
2.2.3 Others
2.3 Bendamustine Sales by Type
2.3.1 Global Bendamustine Sales Market Share by Type (2020-2025)
2.3.2 Global Bendamustine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Bendamustine Sale Price by Type (2020-2025)
2.4 Bendamustine Segment by Application
2.4.1 Chronic Lymphocytic Leukemia
2.4.2 Multiple Myeloma
2.4.3 Non-Hodgkin's Lymphoma
2.5 Bendamustine Sales by Application
2.5.1 Global Bendamustine Sale Market Share by Application (2020-2025)
2.5.2 Global Bendamustine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Bendamustine Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Bendamustine Breakdown Data by Company
3.1.1 Global Bendamustine Annual Sales by Company (2020-2025)
3.1.2 Global Bendamustine Sales Market Share by Company (2020-2025)
3.2 Global Bendamustine Annual Revenue by Company (2020-2025)
3.2.1 Global Bendamustine Revenue by Company (2020-2025)
3.2.2 Global Bendamustine Revenue Market Share by Company (2020-2025)
3.3 Global Bendamustine Sale Price by Company
3.4 Key Manufacturers Bendamustine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Bendamustine Product Location Distribution
3.4.2 Players Bendamustine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Bendamustine by Geographic Region
4.1 World Historic Bendamustine Market Size by Geographic Region (2020-2025)
4.1.1 Global Bendamustine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Bendamustine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Bendamustine Market Size by Country/Region (2020-2025)
4.2.1 Global Bendamustine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Bendamustine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Bendamustine Sales Growth
4.4 APAC Bendamustine Sales Growth
4.5 Europe Bendamustine Sales Growth
4.6 Middle East & Africa Bendamustine Sales Growth
5 Americas
5.1 Americas Bendamustine Sales by Country
5.1.1 Americas Bendamustine Sales by Country (2020-2025)
5.1.2 Americas Bendamustine Revenue by Country (2020-2025)
5.2 Americas Bendamustine Sales by Type (2020-2025)
5.3 Americas Bendamustine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Bendamustine Sales by Region
6.1.1 APAC Bendamustine Sales by Region (2020-2025)
6.1.2 APAC Bendamustine Revenue by Region (2020-2025)
6.2 APAC Bendamustine Sales by Type (2020-2025)
6.3 APAC Bendamustine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Bendamustine by Country
7.1.1 Europe Bendamustine Sales by Country (2020-2025)
7.1.2 Europe Bendamustine Revenue by Country (2020-2025)
7.2 Europe Bendamustine Sales by Type (2020-2025)
7.3 Europe Bendamustine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Bendamustine by Country
8.1.1 Middle East & Africa Bendamustine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Bendamustine Revenue by Country (2020-2025)
8.2 Middle East & Africa Bendamustine Sales by Type (2020-2025)
8.3 Middle East & Africa Bendamustine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Bendamustine
10.3 Manufacturing Process Analysis of Bendamustine
10.4 Industry Chain Structure of Bendamustine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Bendamustine Distributors
11.3 Bendamustine Customer
12 World Forecast Review for Bendamustine by Geographic Region
12.1 Global Bendamustine Market Size Forecast by Region
12.1.1 Global Bendamustine Forecast by Region (2026-2031)
12.1.2 Global Bendamustine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Bendamustine Forecast by Type (2026-2031)
12.7 Global Bendamustine Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Teva
13.1.1 Teva Company Information
13.1.2 Teva Bendamustine Product Portfolios and Specifications
13.1.3 Teva Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Teva Main Business Overview
13.1.5 Teva Latest Developments
13.2 Eisai
13.2.1 Eisai Company Information
13.2.2 Eisai Bendamustine Product Portfolios and Specifications
13.2.3 Eisai Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Eisai Main Business Overview
13.2.5 Eisai Latest Developments
13.3 Eagle Pharmaceuticals
13.3.1 Eagle Pharmaceuticals Company Information
13.3.2 Eagle Pharmaceuticals Bendamustine Product Portfolios and Specifications
13.3.3 Eagle Pharmaceuticals Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Eagle Pharmaceuticals Main Business Overview
13.3.5 Eagle Pharmaceuticals Latest Developments
13.4 MundiPharma
13.4.1 MundiPharma Company Information
13.4.2 MundiPharma Bendamustine Product Portfolios and Specifications
13.4.3 MundiPharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 MundiPharma Main Business Overview
13.4.5 MundiPharma Latest Developments
13.5 Mylan
13.5.1 Mylan Company Information
13.5.2 Mylan Bendamustine Product Portfolios and Specifications
13.5.3 Mylan Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Mylan Main Business Overview
13.5.5 Mylan Latest Developments
13.6 Natco Pharma
13.6.1 Natco Pharma Company Information
13.6.2 Natco Pharma Bendamustine Product Portfolios and Specifications
13.6.3 Natco Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Natco Pharma Main Business Overview
13.6.5 Natco Pharma Latest Developments
13.7 Emcure
13.7.1 Emcure Company Information
13.7.2 Emcure Bendamustine Product Portfolios and Specifications
13.7.3 Emcure Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Emcure Main Business Overview
13.7.5 Emcure Latest Developments
13.8 Miracalus Pharma
13.8.1 Miracalus Pharma Company Information
13.8.2 Miracalus Pharma Bendamustine Product Portfolios and Specifications
13.8.3 Miracalus Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Miracalus Pharma Main Business Overview
13.8.5 Miracalus Pharma Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂